TCGA-OR-A5K6-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.385
- PEROXISOME+0.311
- MYC_TARGETS_V1+0.280
- FATTY_ACID_METABOLISM+0.276
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.255
- OXIDATIVE_PHOSPHORYLATION+0.199
- BILE_ACID_METABOLISM+0.172
- XENOBIOTIC_METABOLISM+0.170
- MYC_TARGETS_V2+0.142
- IL6_JAK_STAT3_SIGNALING+0.123
Top 10 suppressed
- G2M_CHECKPOINT-0.287
- E2F_TARGETS-0.263
- MITOTIC_SPINDLE-0.224
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.168
- ANGIOGENESIS-0.156
- GLYCOLYSIS-0.137
- UV_RESPONSE_DN-0.136
- PANCREAS_BETA_CELLS-0.123
- HYPOXIA-0.113
- APICAL_JUNCTION-0.085
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG105 | — | — | 0.690 |
| 2 | MNG658 | — | — | 0.662 |
| 3 | SRR9879284 | — | cohortA1 | 0.650 |
| 4 | MNG112 | — | — | 0.639 |
| 5 | TCGA-OR-A5L3-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.634 |
| 6 | 130692 | EPN | Supratentorial EPN | 0.621 |
| 7 | SRR8518247 | — | F | 0.603 |
| 8 | SRR15030860 | — | — | 0.602 |
| 9 | DRR168583 | — | — | 0.598 |
| 10 | 8f673a13-7f81-4685-a415-645ff6b5e2fb | — | — | 0.597 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.385 | Remibrutinib | — uncovered |
| PEROXISOME | 0.311 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.280 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.276 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.255 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.199 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.172 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.170 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.142 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.123 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.093 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.091 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.073 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.060 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.054 | Inavolisib | — uncovered |
| COAGULATION | 0.051 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.040 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.024 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.006 | Idelalisib | — uncovered |